Almac's clinical Supply Chain Management service combines consultancy and supportive technology that helps sponsor companies
Almac’s best-in-class clinical Supply Chain Management (SCM) service combines consultancy and supportive technology that helps sponsor companies overcome technological, logistical and planning challenges increasingly experienced by biotech and pharma companies conducting global clinical trials.
As clinical studies become truly global, sponsor companies face challenges with shorter availability of complex investigational products, variable patient demands and the pressures on an increasingly stretched global supply chain. Coupled with the need for global provision of expensive comparators, sponsors are seeking oversight across all aspects of their clinical supply chain.
Almac have continued developing their unique SCM service that blends consultancy, supportive technology and end-to-end supply chain visibility. This gives sponsors more control over the complete supply chain, driving down costs, reducing timeframes and aligning clinical supply with patient demand globally.
The Almac solution of single system integration of forecasting, Material Resource Planning (MRP) and Interactive Response Technology (IRT) provides data in real-time. As a consequence, the dedicated SCM experts are able to assume responsibility to make key decisions, thereby ensuring reliable and efficient supply of clinical trial material to meet patient demand.
Almac’s latest service offering further enhances and supplements their core manufacturing, packaging and distribution services for investigational products and offers clients the best and most comprehensive clinical supply chain management solution available on the global marketplace.
Michelle Foust, Almac’s Director of Supply Chain Strategy stated “Almac has been providing clinical SCM for over 25 years and in response to the challenges experienced by our global client base, we have developed novel solutions for use across multiple study types. Indeed, we are confident that our consultancy-based offering optimizes clinical trial supply, thereby minimising waste and decreasing costs for our partners.”
Find out more about clinical Supply Chain Management – http://www.almac-scm.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.